Descripción del proyecto
Una terapia de expansión celular «ex vivo» para el infarto de miocardio
El infarto de miocardio, también conocido como «ataque al corazón», se produce cuando el corazón no recibe una cantidad suficiente de oxígeno debido a la disminución del flujo sanguíneo. Esto causa daños del miocardio y, dependiendo del alcance de la lesión, puede causar una insuficiencia cardíaca. El proyecto financiado con fondos europeos EuroXpand tiene por objeto mejorar el remodelado cardíaco tras un infarto por medio de un enfoque de medicina regenerativa. El equipo ha desarrollado un enfoque hematopoyético autólogo basado en células madre que mejora la función cardíaca tras una infusión. Las células se expanden «ex vivo» en condiciones estandarizadas, por medio de una plataforma de bioproducción de diseño propio y patentado, para cumplir los criterios de calidad y de reproducibilidad con un menor coste.
Objetivo
Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development.
In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion.
The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%.
With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 2,7 billion euros in 2030, associated to the creation of at least 70 direct jobs by 2027 and several thousands of indirect jobs, particularly in Cell Therapy Centres.
Ámbito científico
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinesurgerysurgical procedures
- medical and health sciencesclinical medicineoncology
- medical and health sciencesclinical medicinecardiology
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-2-2016-2017
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
68100 MULHOUSE
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.